Angiodynamics INC Form 4 insider transactions

AngioDynamics President and CEO, James C. Clemmer, disposed of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

AngioDynamics SVP/GM Chad Thomas Campbell reported the disposition of 1,779 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

AngioDynamics Inc.'s SVP International, Laura Piccinini, reported the future disposition of 3,074 common shares at $8.74 each to cover tax withholding from a restricted stock unit vesting scheduled for July 17, 2025.

AngioDynamics, Inc. SVP Quality and Regulatory, Warren Nighan Jr., was granted 29,349 restricted stock units and 29,349 performance rights, aligning executive incentives with long-term shareholder value.

AngioDynamics Inc. CEO James C. Clemmer was granted 206,253 restricted stock units and 206,253 performance rights, aligning executive compensation with long-term shareholder value.

AngioDynamics' SVP and Chief Legal Officer, Lawrence T. Weiss, was granted 30,900 restricted stock units and 30,900 performance rights on July 16, 2025, as part of his compensation.

AngioDynamics' Executive Vice President and Chief Financial Officer, Stephen A. Trowbridge, was granted 86,997 restricted stock units and 86,997 performance rights, aligning his compensation with future company performance.

AngioDynamics, Inc. discloses a future equity grant to SVP/GM Chad Campbell, comprising restricted stock units and performance rights, set to vest over several years based on time and performance.

AngioDynamics Inc. Director Howard W. Donnelly was granted 17,675 shares of common stock as part of his regular annual compensation, immediately vesting upon grant.

AngioDynamics Inc. Director Lorinda Burgess was granted 17,675 shares of common stock as part of her regular annual compensation, which vested immediately.

AngioDynamics Inc.'s SVP International, Laura Piccinini, was granted 32,423 restricted stock units and 32,423 performance rights, aligning executive incentives with shareholder returns.

AngioDynamics Inc. Director Eileen O'Shea Auen was granted 17,675 restricted stock units as annual compensation, which vested immediately upon grant.

AngioDynamics, Inc. Director Michael E. Tarnoff was granted 17,675 restricted stock units as part of his regular annual compensation, which vested immediately.

AngioDynamics Inc. Director Jan S. Reed acquired 17,675 shares of common stock as part of her regular annual compensation, immediately vesting upon grant.

AngioDynamics, Inc. Director Karen A. Licitra acquired 17,675 shares of common stock as part of her regular annual compensation, bringing her total beneficial ownership to 90,435 shares.

AngioDynamics Inc. Director Wesley Johnson was granted 17,675 restricted stock units as part of his annual compensation, which vested immediately.

Warren Nighan JR, SVP of Quality and Regulatory at AngioDynamics, sold 4,060 shares of common stock at a price of $12.31 per share on January 16, 2025.

Lawrence T. Weiss, SVP and Chief Legal Officer at AngioDynamics, received a grant of restricted stock units and stock options.

Warren Nighan JR, SVP of Quality and Regulatory at AngioDynamics Inc, reports purchasing additional shares of common stock.

Stephen Trowbridge, EVP and CFO of AngioDynamics Inc., purchased 1,700 shares of common stock at $5.86 per share on October 8, 2024.

AngioDynamics' CEO, James C. Clemmer, recently acquired 20,000 shares of the company's common stock at an average price of $6.03 per share.

Laura Piccinini, SVP International at AngioDynamics, reports the acquisition and disposition of common stock related to the vesting of performance share units.

AngioDynamics CEO James C. Clemmer acquired 56,279 shares of common stock through the vesting of performance share units and disposed of 28,730 shares to cover tax obligations.

Warren Nighan Jr., SVP of Quality and Regulatory at AngioDynamics, reports acquisition and disposition of company stock related to performance share units.

Chad Thomas Campbell, SVP/GM, Vascular Access at AngioDynamics, reports acquisition and disposition of common stock related to performance share units.

Stephen Trowbridge, EVP and CFO of AngioDynamics, reports the acquisition and disposition of company shares related to vesting of performance share units and restricted stock units.

Chad Thomas Campbell, SVP/GM, Vascular Access at AngioDynamics, Inc., disposed of shares to satisfy tax withholding obligations related to vesting restricted stock units.

Laura Piccinini, SVP International at AngioDynamics, disposed of shares to satisfy tax withholding obligations related to vesting restricted stock units.

AngioDynamics CEO James Clemmer disposed of shares to satisfy tax withholding obligations related to vesting restricted stock units.

Warren Nighan JR, SVP of Quality and Regulatory at AngioDynamics, reports disposing of shares to cover tax withholding obligations related to vesting restricted stock units.